MedTrace Logo

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

NCT04180982 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2019-12-02

No results posted yet for this study

Summary

The objective of the study is to assess the Safety and Efficacy of SHR4640 and Febuxostat in patients with Hyperuricemia.

Conditions

  • Hyperuricemia

Interventions

DRUG

SHR4640 dose1 plus Febuxostat dose1

Tablet,dose1,QD

DRUG

SHR4640 dose1 plus Febuxostat dose2

Tablet,dose1, dose2 QD

DRUG

SHR4640 dose2 plus Febuxostat dose3

Tablet,dose2, dose3 QD

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Liu Yi · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-03
Primary Completion
2020-07-30
Completion
2020-08-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04180982 on ClinicalTrials.gov